Pharmacological studies of long-acting phenothiazines with particular reference to fluphenazine decanoate
نویسندگان
چکیده
منابع مشابه
Fluphenazine Decanoate in Chronic Schizophrenia
Introduction of chlorpromazine by Delay and Danikcr in 1952 revolutionized the treatment of acute schizophrenia. However, chronic form of the illness still remains a challenge, mainly because of noncompliance of the patients with the therapeutic regimen (Diamond and Marks, 1960; Olson and Peterson, 1960; Hare and Willcox, 1967 ; Wilson and Enoch, 1967 and Ayd, 1975). Another factor is the errat...
متن کاملQuantitation of fluphenazine in equine serum following fluphenazine decanoate administration.
Fluphenazine, a potent antipsychotic used to treat schizophrenia in humans, is used in racehorses as a performance-enhancing drug, and for that reason it has been banned by the Association of Racing Commissioners International. A liquid chromatography-tandem mass spectrometry method for detecting and quantitating fluphenazine in equine serum was developed and validated. The method was then empl...
متن کاملSide effects of parenteral long-acting phenothiazines.
There are other intriguing features of the present case. At no time was the patient hypertensive, in contrast to the usual situation in Conn's syndrome or bilateral adrenal hyperplasia. As Conn (1964) pointed out, however, the rise in pressure is variable and in the early stages may be minimal. The observations on blood pressure harmonize also with the measurements of plasma renin activity. In ...
متن کاملTreatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
OBJECTIVE This study compares 3 cohorts of patients with schizophrenia before, during, and after initiating treatment with fluphenazine decanoate (FD), haloperidol decanoate (HD), or long-acting injectable risperidone (LAR). METHODS Administrative data are analyzed from California Medicaid (Medi-Cal) beneficiaries with schizophrenia who initiated FD, HD, or LAR treatment. Patients were requir...
متن کاملNumber needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
BACKGROUND We analyzed data retrieved through a PubMed search of randomized, placebo-controlled trials of first-generation antipsychotic long-acting injectables (haloperidol decanoate, bromperidol decanoate, and fluphenazine decanoate), and a company database of paliperidone palmitate, to compare the benefit-risk ratio in patients with schizophrenia. METHODS From the eight studies that met ou...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Folia Pharmacologica Japonica
سال: 1978
ISSN: 0015-5691,1347-8397
DOI: 10.1254/fpj.74.871